Acuta Capital Partners LLC Has $3.18 Million Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Acuta Capital Partners LLC increased its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 165.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 771,958 shares of the company's stock after purchasing an additional 481,458 shares during the quarter. Trevi Therapeutics makes up about 3.2% of Acuta Capital Partners LLC's portfolio, making the stock its 11th largest holding. Acuta Capital Partners LLC owned about 1.00% of Trevi Therapeutics worth $3,180,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently modified their holdings of the company. Summit Investment Advisors Inc. increased its position in Trevi Therapeutics by 84.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock valued at $26,000 after acquiring an additional 2,894 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Trevi Therapeutics by 2.1% during the 4th quarter. Bank of New York Mellon Corp now owns 140,219 shares of the company's stock worth $578,000 after purchasing an additional 2,935 shares in the last quarter. SG Americas Securities LLC grew its stake in Trevi Therapeutics by 14.5% in the fourth quarter. SG Americas Securities LLC now owns 26,792 shares of the company's stock valued at $110,000 after acquiring an additional 3,387 shares during the period. Invesco Ltd. increased its stake in Trevi Therapeutics by 21.2% during the 4th quarter. Invesco Ltd. now owns 23,621 shares of the company's stock valued at $97,000 after purchasing an additional 4,133 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Trevi Therapeutics by 32.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 25,166 shares of the company's stock worth $104,000 after buying an additional 6,119 shares during the last quarter. 95.76% of the stock is currently owned by institutional investors.

Insider Activity

In other Trevi Therapeutics news, CEO Jennifer L. Good sold 5,263 shares of the firm's stock in a transaction dated Friday, March 21st. The shares were sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the sale, the chief executive officer now directly owns 213,313 shares in the company, valued at $1,403,599.54. This trade represents a 2.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Farrell Simon sold 81,313 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the transaction, the insider now owns 76,900 shares in the company, valued at $519,075. This trade represents a 51.39 % decrease in their position. The disclosure for this sale can be found here. Insiders own 24.37% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently commented on TRVI. Raymond James raised Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their price objective for the stock from $9.00 to $29.00 in a research note on Monday, March 10th. D. Boral Capital reaffirmed a "buy" rating and set a $21.00 price objective on shares of Trevi Therapeutics in a report on Wednesday, March 19th. B. Riley reissued a "buy" rating and set a $20.00 price target (up from $11.00) on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. HC Wainwright reaffirmed a "buy" rating and set a $12.50 target price on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 price target on shares of Trevi Therapeutics in a report on Tuesday, April 8th. Seven research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, Trevi Therapeutics currently has a consensus rating of "Buy" and an average target price of $17.56.

Trevi Therapeutics Stock Down 0.1 %

Trevi Therapeutics stock opened at $6.90 on Friday. The stock has a market cap of $667.11 million, a price-to-earnings ratio of -15.68 and a beta of 0.41. The business has a 50-day simple moving average of $5.88 and a 200 day simple moving average of $4.37. Trevi Therapeutics, Inc. has a 52 week low of $2.30 and a 52 week high of $7.39.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.01. On average, research analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.

Want to see what other hedge funds are holding TRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.